Healius (ASX:HLS) announces CEO succession

• Healius’ (HLS) CEO and Managing Director, Dr Malcolm Parmenter, announces his resignation
• As a result of the move, Healius’ current CFO and COO Maxine Jaquet will step into the role from March 1, 2023
• The new appointment comes with a $1.5 million annual salary, along with short and long term incentives
• Healius’ Chair Jenny Macdonald told investors Maxine will hit the ground running given the pivotal role she has played in the company to date
• Healius shares are down 1.91 per cent, trading at $2.83 at 12:49 pm AEDT

Healius’ (HLS) Chief Executive Officer and Managing Director, Dr Malcolm Parmenter, has announced his resignation.

Dr Parmenter held the role of Chief Executive Officer since September 2017 during which time he oversaw a “period of turnaround” in the company, including embarking on a foundational digital agenda and re-orienting the business to be in service of patients and clinicians.

As a result of the move, Healius’ current CFO and COO Maxine Jaquet will step into the role from March 1, 2023.

Ms Jaquet first joined Healius’ leadership team in 2015, having been Chief Financial Officer since August 2019.

“Following discussions earlier this year with Malcolm on his timelines and tenure, the board has undertaken a thorough succession planning process and is delighted to be able to appoint an executive of Maxine’s calibre and experience to the role of CEO,” Healius Chair Jenny Macdonald said.

“Maxine will hit the ground running given the pivotal role she has played in leading the portfolio reshaping, refocusing Healius as a diagnostics operator, divesting medical centres, and her contribution to fortifying the balance sheet, improving cash generation and structurally improving margins.”

The appointment comes with a $1.5 million annual salary, along with short and long term incentives.

Healius shares were down 1.91 per cent, trading at $2.83 at 12:49 pm AEDT.